AR073459A1 - COMPOSITIONS OF VARIABLE DOMAINS OF MONOVALENT ANTIBODIES FOR THE UNION OF CD28 AND METHODS OF USE - Google Patents
COMPOSITIONS OF VARIABLE DOMAINS OF MONOVALENT ANTIBODIES FOR THE UNION OF CD28 AND METHODS OF USEInfo
- Publication number
- AR073459A1 AR073459A1 ARP090102733A ARP090102733A AR073459A1 AR 073459 A1 AR073459 A1 AR 073459A1 AR P090102733 A ARP090102733 A AR P090102733A AR P090102733 A ARP090102733 A AR P090102733A AR 073459 A1 AR073459 A1 AR 073459A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- variable domain
- monovalent
- methods
- single variable
- Prior art date
Links
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 title abstract 10
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 title abstract 10
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 abstract 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000003993 interaction Effects 0.000 abstract 2
- 229940122262 CD28 antagonist Drugs 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
Se relaciona con un dominio de polipéptido monovalente que se une de manera específica a CD28, al igual que con un antagonista de CD28, donde el antagonista comprende un dominio de polipéptido monovalente que se une de manera especifica a CD28. Dominios de polipéptidos monovalentes que comprenden un dominio variable simple de anticuerpo que se une de manera monovalente a CD28. Un dominio variable simple de anticuerpo que es monovalente para la union de CD28 puede inhibir la actividad de CD28. En un aspecto, un dominio variable simple de anticuerpo anti-CD28 monovalente comprende o consiste en un dominio variable simple de anticuerpo que se une de manera específica a CD28 y antagonista su actividad, en un aspecto, sin agonizar de manera sustancial la actividad de CD28. En otro aspecto, el dominio variable simple de anticuerpo anti-CD28 monovalente es un dominio variable simple de anticuerpo humano. Además contempla métodos para la antagonizacion de las interacciones de CD80 y/o CD86 con CD28 en un individuo, y métodos para el tratamiento de enfermedades o trastornos que involucran interacciones de CD80 y/o CD86 con CD28; donde los métodos comprenden la administracion de un dominio variable simple de anticuerpo anti-CD28 monovalente al individuo.It relates to a monovalent polypeptide domain that specifically binds to CD28, as well as a CD28 antagonist, where the antagonist comprises a monovalent polypeptide domain that specifically binds to CD28. Monovalent polypeptide domains comprising a single variable domain of antibody that binds monovalently to CD28. A simple variable domain of antibody that is monovalent for CD28 binding can inhibit CD28 activity. In one aspect, a single variable domain of monovalent anti-CD28 antibody comprises or consists of a single variable domain of antibody that specifically binds to CD28 and antagonizes its activity, in one aspect, without substantially agonizing CD28 activity. . In another aspect, the single variable domain of monovalent anti-CD28 antibody is a simple variable domain of human antibody. It also contemplates methods for the antagonization of the interactions of CD80 and / or CD86 with CD28 in an individual, and methods for the treatment of diseases or disorders that involve interactions of CD80 and / or CD86 with CD28; where the methods comprise the administration of a single variable domain of monovalent anti-CD28 antibody to the individual.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US755308P | 2008-07-18 | 2008-07-18 | |
| US17603608A | 2008-07-18 | 2008-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073459A1 true AR073459A1 (en) | 2010-11-10 |
Family
ID=41316544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090102733A AR073459A1 (en) | 2008-07-18 | 2009-07-17 | COMPOSITIONS OF VARIABLE DOMAINS OF MONOVALENT ANTIBODIES FOR THE UNION OF CD28 AND METHODS OF USE |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP2315778A2 (en) |
| JP (1) | JP2012507260A (en) |
| AR (1) | AR073459A1 (en) |
| WO (1) | WO2010007376A2 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4420663A3 (en) | 2013-12-20 | 2024-10-30 | Novartis AG | Regulatable chimeric antigen receptor |
| ES2857226T3 (en) | 2014-03-15 | 2021-09-28 | Novartis Ag | Regulable chimeric antigen receptor |
| WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| EP3660042B1 (en) | 2014-07-31 | 2023-01-11 | Novartis AG | Subset-optimized chimeric antigen receptor-containing t-cells |
| CN106397592A (en) * | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | Single-domain antibody directed at programmed death ligand (PD-L1) and derived protein thereof |
| EA038179B1 (en) * | 2015-11-18 | 2021-07-20 | Мерк Шарп И Доум Корп. | Ctla4 binders |
| KR102220275B1 (en) | 2015-11-18 | 2021-02-26 | 머크 샤프 앤드 돔 코포레이션 | Pd1 and/or lag3 binders |
| BR112018013677A2 (en) | 2016-01-11 | 2019-01-22 | Inhibrx Inc | multivalent and multispecific 41bb binding fusion proteins |
| CN107400166A (en) * | 2016-05-19 | 2017-11-28 | 苏州康宁杰瑞生物科技有限公司 | for CTLA4 single domain antibody and its derived protein |
| CN112638375A (en) | 2018-06-15 | 2021-04-09 | 旗舰创业创新五公司 | Increasing immune activity through modulation of post-cellular signaling factors |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| WO2021127217A1 (en) | 2019-12-17 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| MX2022009306A (en) * | 2020-01-29 | 2022-09-26 | Inhibrx Inc | Cd28 single domain antibodies and multivalent and multispecific constructs thereof. |
| EP4172323A1 (en) | 2020-06-29 | 2023-05-03 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| US12195546B2 (en) * | 2022-12-19 | 2025-01-14 | Sanofi | CD28/OX40 bispecific antibodies |
| US20240269251A1 (en) | 2023-01-09 | 2024-08-15 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| CN119285779A (en) * | 2023-11-20 | 2025-01-10 | 上海百英生物科技股份有限公司 | An anti-CD28 nano antibody and its preparation method and application |
| WO2025257408A1 (en) * | 2024-06-14 | 2025-12-18 | Sanofi | Treatment of solid organ transplant subjects with cd28/ox40 bispecific antibodies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6051227A (en) * | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| US8907065B2 (en) * | 2006-12-15 | 2014-12-09 | Ablynx N.V. | Polypeptides that modulate the interaction between cells of the immune system |
-
2009
- 2009-07-17 EP EP09784717A patent/EP2315778A2/en not_active Withdrawn
- 2009-07-17 JP JP2011517992A patent/JP2012507260A/en active Pending
- 2009-07-17 WO PCT/GB2009/001762 patent/WO2010007376A2/en not_active Ceased
- 2009-07-17 AR ARP090102733A patent/AR073459A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010007376A3 (en) | 2010-05-27 |
| EP2315778A2 (en) | 2011-05-04 |
| JP2012507260A (en) | 2012-03-29 |
| WO2010007376A2 (en) | 2010-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073459A1 (en) | COMPOSITIONS OF VARIABLE DOMAINS OF MONOVALENT ANTIBODIES FOR THE UNION OF CD28 AND METHODS OF USE | |
| CO6341641A2 (en) | MONOVALENT COMPOSITIONS FOR UNION TO CD28 AND METHODS OF USE | |
| BR112013007314A2 (en) | anti-cd48 antibodies and their uses | |
| BR112012023010A2 (en) | "antibody or antigen binding fragment thereof which specifically binds to cd37, immunoconjugate comprising them, use of said antibody, fragment and immunoconjugate, composition comprising them, kit, isolated cell, as well as in vitro method for inhibiting growth" of a cell expressing cd37 " | |
| EA201491161A1 (en) | FLUORINATED ESTROGEN RECEPTOR MODULATORS AND THEIR APPLICATION | |
| EP2331136A4 (en) | Frizzled-binding agents and uses thereof | |
| UA109633C2 (en) | HUMAN ANTIBODY AGAINST TISSUE FACTOR | |
| AR077333A1 (en) | HIGH AFFINITY HUMAN ANTIBODIES FOR HUMAN ANGIOPOYETIN -2 | |
| EA201370066A1 (en) | MODULATORS OF ESTROGEN RECEPTORS AND THEIR APPLICATION | |
| EA201270815A1 (en) | ESTROGEN RECEPTOR MODULATORS AND THEIR APPLICATION | |
| EA201071291A2 (en) | NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROPSYATRIC DISORDERS | |
| EA201390472A1 (en) | NEW MOLECULES CONNECTING WITH EGFR AND THEIR IMMUNOCONJUGATES | |
| EA201270720A1 (en) | ANDROGEN RECEPTOR MODULATORS AND THEIR APPLICATION | |
| MY159679A (en) | Antibodies binding preferentially human csf1r extracellular domain 4 and their use | |
| BR112015014751A2 (en) | human anti-tau antibodies | |
| EA200901166A1 (en) | CONNECTIONS AND COMPOSITIONS AS GPR 119 ACTIVITY MODULATORS | |
| BRPI1009381B8 (en) | compounds, pharmaceutical composition and use of compounds and pharmaceutical composition | |
| EA201390813A1 (en) | ANTIBODIES AND THEIR APPLICATION | |
| UY31622A1 (en) | ANTHOGONISTS OF AMINOALQUILBIFENILO N, N-DISUBSTITUIDOS OF PROSTAGLANDINA D2 RECEPTORS | |
| BR112012018766A2 (en) | methods of treating autoimmune diseases with dll4 antagonists. | |
| MX2019012461A (en) | Anti-pd-l1 antibody and use thereof. | |
| PE20141158A1 (en) | THE PROLACTIN MAT3 RECEPTOR NEUTRALIZING ANTIBODY AND ITS THERAPEUTIC USE | |
| ECSP099296A (en) | IMMUNO-REGULATORS, PREPARATIONS AND COMPOSITIONS INCLUDING IMMUNO-REGULATORS, TESTS TO EVALUATE THE ACTIVITY OF IMMUNO-REGULATORS AND PREPARATIONS AND COMPOSITIONS INCLUDING THE SAME AND METHODS | |
| EA201291180A1 (en) | COMPOSITIONS AND METHODS OF APPLICATION OF THERAPEUTIC ANTIBODIES AGAINST PROTEIN RELATED TO LOW DENSITY 6 LIPOPROTEIN RECEPTOR (LRP6) | |
| EA200602243A1 (en) | 3-AMINOCYCLOPENTANCARBOXAMIDES AS CHEMOKINE RECEPTOR MODULATORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |